ReviewThe Medical clinics of North America2018
Prostate Cancer Screening.
Review in The Medical clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Knowledge of prostate cancer presentation, etiology, and screening practices among women: a mixed-methods systematic review.Systematic reviews · 2021Pooled it
- Effect of Prostate Cancer Education on Saudi Men: Knowledge, Beliefs, and Screening Intentions.Asian Pacific journal of cancer prevention : APJCP · 2024Trial
- Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.Nutrients · 2023Trial
- Combined ADC and TMagnetic resonance in medicine · 2026Article
- Urinary DNA Methylation Profiling Improves Discrimination of Prostate Cancer Across PSA-Defined Risk Strata.Biochemical genetics · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.Discover oncology · 2026Article
- Prostate cancer screening and evidence: the role of overall survival.Translational andrology and urology · 2026Article
- Cost-effectiveness of cancer screening and overall survival benefit.Translational cancer research · 2026Article
- Urine-Based Machine Learning Assay Detects Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Is Standard TRUS-Guided Prostate Biopsy the End of the Game?Urology research & practice · 2026Article
- Article
- Detection of Prostate Carcinoma in an Asymptomatic Individual Initiated by an Immunological Biopsy-A Case Report.Oncology research · 2026Article
- Affordable ultrasensitive electrochemical detection of PCA3 for early prostate cancer diagnosis.Scientific reports · 2025Article
- From bench to bedside: the evolution and future of prostate-specific antigen testing.Medical oncology (Northwood, London, England) · 2025Review
- Prostate Cancer Mortality Trend in Montenegro 1990-2018.Iranian journal of public health · 2025Article
- RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.International journal of molecular sciences · 2025Article
- Microbiome in prostate cancer: pathogenic mechanisms, multi-omics diagnostics, and synergistic therapies.Journal of cancer research and clinical oncology · 2025Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.